Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 12 Nov 2025 for Evommune, Inc.. Read the official filing
Filing timeline
BuySalePivotal bioVenture Partners Fund I, L.P.
Insider track record
Disclosed buys
2
Disclosed sells
0
Signal history
Closed purchases
Market purchases
2
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Pivotal bioVenture Partners Fund I, L.P.: trading record in brief
Pivotal bioVenture Partners Fund I, L.P. is a declared insider at 2 companies; the most frequent names are Inozyme Pharma, Inc. and Evommune, Inc. Between 19 April 2022 and 7 November 2025, the trades on record add up to 3 filings.
On the market, this insider has only ever bought: 2 purchases, €4.2M in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
The newest entry dates from 12 November 2025: a transaction, in Evommune, Inc. The most recent open-market purchase was published on 3 August 2023, 1,172 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Pivotal bioVenture Partners Fund I, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
1,441,032 sharesCommon StockSEC:0001012975-25-000730:0
119,048 shares@ US$4.8012.4% of flowCommon StockSEC:0000950170-23-038272:0
Canonical exit: 30 Oct 2023 (T+90)
▲
Same trade as the filing by Robert Lorne Hopfner, counted once · View ↗
1,070,000 shares@ US$3.6987.6% of flowCommon StockSEC:0001062993-22-010574:0
Canonical exit: 18 Jul 2022 (T+90)
3 of 2 declarations
